Profile
CPTx's platform technology and proprietary manufacturing position CPTx as a leader in therapeutics developed with DNA single strands synthesis. CPTx is advancing an in vivo CAR T-cell therapy through preclinical development with an expected IND filing in 2027. In addition, CPTx is developing a self-delivering gene nanocarrier platform built with single-stranded DNA designed to target specific cell types and tissues to safely and effectively deliver genes. CPTx has headquarters and a manufacturing facility in Munich, and its U.S. subsidiary, CPTx, Inc., has an office in South San Francisco, California.
Pioneering precision medicines, faster.
We are biotechnology and engineering experts, building advanced medicines from the ground up with precision and innovation.
Using proprietary technologies including programmable single-stranded DNA fabrication and AI-supported molecular design, we overcome existing development challenges to bring new therapies to market.
Our goal? To develop effective and safe advanced therapies for unmet medical needs.
Contact Info
Phone: +49 (0) 89 6933 0382
Email: info@cptx.bio
Address
CPTx, Semmelweisstr. 1, 82152 Planegg, Germany
611 Gateway Boulevard, Suite 120, South San Francisco, CA 94080, United States of America